TOPLINE:
Janus kinase (JAK) inhibitors were associated with more infections, particularly herpes infections, in patients with atopic dermatitis (AD) compared with biologics, in a cohort study.
METHODOLOGY:
- A prospective, multicenter observational study included 1793 patients (age, ≥ 12 years) with moderate to severe AD from the Dutch BioDay registry between October 2017 and July 2024.
- The patients received biologics (dupilumab and tralokinumab) or a JAK inhibitor (abrocitinib, baricitinib, and upadacitinib).
- The researchers monitored treatment-emergent infections.
TAKEAWAY:
- A total of 512 patients experienced 794 infections (incidence rate, 19.6/100 patient-years). Most were mild (30.6%) or moderate (62.5%).
- JAK inhibitors were associated with higher infection rates (58.4-65.5/100 patient-years) than with biologics…